[1], [1,5] CR-BSI [9] [10,11] [12,13] [14] [15] [16] CR-BSI [17] CDC ICU 1,000 CR-BSI ICU CR-BSI 1, [18] CR-BSI CR-BSI CR-B
|
|
|
- きよたつ うなだ
- 5 years ago
- Views:
Transcription
1 16 Povidone-iodine [2] 20 [3] Semiquatitative roll-plate 15CFU(CFU:colony-forming unit) [6] 1000CFU [7] 5 ( CR-BSI)
2 [1], [1,5] CR-BSI [9] [10,11] [12,13] [14] [15] [16] CR-BSI [17] CDC ICU 1,000 CR-BSI ICU CR-BSI 1, [18] CR-BSI CR-BSI CR-BSI CR-BSI Pittet CR-BSI [19-21] DiGiovine ICU CR-BSI 4.4 (p=0.51)[22] Soufir CR-BSI [23] CR-BSI CR-BSI 6,005 9, ,000 [17,19,20]
3 [24] Eyer 7 [25] Cobb [26] [24] [27,28] 16.1 Maximum sterile barrier MSB CR-BSI MSB MSB MSB MSB MSB MSB 176 MSB 167 [29]
4 MSB [30] * ( 95 ) 500 1, CR-BSI:1, MSB 1 : 2.3% 7.2% (p=0.04) ( ) ( )[29] : , (p=0.02) 2, 6 ICU 1 28% (p<0.01) 1 44% 65% (p<0.001) [30] 1A, CR-BSI 1 : 0.56 ( ) [44] , CR-BSI : 1 0.3% 3.4% (p<0.002) 10
5 [46] 7 1A, : RR 0.56 (0.31-1) : RR 0.71 ( ) : RR 0.61 ( ) [61] 1 1 : RR 0.59 ( ) 1A, CR-BSI: RR 0.26 ( ) 1 : RR 0.18 ( ) 12 :RR CR-BSI(4 ) (7 )[59] ( ) 1A, : RR 1.26 ( ) 3 1 : RR 1.72 ( ) 12 : RR 0.48 ( ) [24] * RR : RR 1.52 ( ) 3 MSB
6 MSB MSB Sherertz 74,081 [30] MSB [29,30] MSB MSB MSB MSB 16.2 CR-BSI [31 43] [44]
7 [45] [46] CR-BSI CR-BSI * ( ( ) ) Tennenberg[31]: 137, Maki[32]: 158 ICU , 5.1, 5.3 SQ (IV, SC, >15 CFU) 86 CFU) , SQ (IV, >15 SO (IV, SC, site), CS, NS SO (>15 CFU, IV, hub, inf) van Heerden[33] : 54 ICU 28, 6.6, SQ (IV, >15 NR ( ); 6.8 CFU) 3 Hannan[34]: ICU 68, 7, SQ (IV, SO (IV, > >10 3 CFU) CFU), NS
8 Bach[35] : 26 ICU (14 14, ); 3 7.0, QN (IV, >10 3 CFU) NR Bach[36] : 133 ( , 7.7, QN (IV, SO (IV) ); 7.7 >10 3 CFU) 2 3 Heard[37] : 111 ICU 151, 8.5, SQ (IV, SC, SO (IV, SC, ( ); 9 >14 CFU) >4 CFU) 3 Collin[38]: 119 ER/ICU 98, ( ); , 7.3 SQ (IV, SC, >15 CFU) SO (IV, SC) Ciresi[39] : , 9.6, SQ (IV, SC, SO (IV, SC) ( ); 9.1 >15 CFU) 3 Pemberton[40]: 72 32, 10, NR SO (IV), Res, ( ); 11 NS 3 Ramsay[41] : , 10.9, SQ (IV, SC, ( >15 CFU) SO (IV, SC)
9 ) Trazzera[42] : 181 ICU/BMT 123, 11.2, SQ (IV, >15 SO (IV, >15 ( ); 6.7 CFU) CFU) 3 George[43]: ; 44, 3 35 NR SQ (IV, >5 CFU) SO (IV) * BMT CFU colony forming units; CS ; ER ; ICU ; IV ; inf ; NR ; NS ; QN ; Res ; SC ; SICU ; site ; SO ; SQ ; TPN (1/98-3/98 ) * (95% (95% ) ) Tennenberg [31] 8 (5.8%) 32 (22.1%) 0.22 ( ) Maki[32] 28 (13.5%) 47 (24.1%) 0.49 ( ) 5 (3.6%) 9 (6.2%) 0.57 ( ) 2 (1.0%) 9 (4.6%) 0.20 ( )
10 van Heerden [33] 4 (14.3%) 10 (38.5%) 0.27 ( ) Hannan[34] 22 (32.4%) 22 (36.7%) 0.83 ( ) 5 (7.4%) 7 (11.7%) 0.60 ( ) Bach[35] 0 (0%) 4 (33.3%) 0 (0-0.65) Bach[36] 2 (1.7%) 16 (13.7%) 0.11 ( ) Heard[37] 60 (39.7%) 82 (52.2%) 0.60 ( ) Collin[38] 2 (2.0%) 25 (18.0%) 0.10 ( ) Ciresi[39] 15 (12.1%) 21(16.5%) 0.69 ( ) 0 (0%) 3 (2.6%) 0 (0-1.28) 5 (3.3%) 6 (3.8%) 0.86 ( ) 1 (1.0%) 4 (2.9%) 0.35 ( ) 13 (10.5%) 14 (11.0%) 0.95 ( ) Pemberton [40] 2 (6.3%) 3 (7.5%) 0.82 ( ) Ramsay[41] 45 (22.6%) 63 (33.3%) 0.58 ( ) Trazzera[42] 16 (13.0%) 24 (24.2%) 0.47 ( ) George[43] 10 (22.7%) 25 (71.4%) 0.12 ( ) 1 (0.5%) 4 (2.1%) 0.23 ( ) 4 (3.3%) 5 (5.1%) 0.63 ( ) 1 (2.3%) 3 (8.6%) 0.25 ( ) *CI CR-BSI [44] CR-BSI CR-BSI
11 ,p< [46] 13 1 [47] 117,000 [47] 2 10 CR-BSI 200 [47] 9 [46] 2 10
12 16.3 Chlorhexidine Gluconate Povidone-iodine [9,12-14] 10 CR-BSI [52] [48 53] (CHG) povidone-iodine ( ) * Maki[48]: 441 ICU (2% CHG , , 5.3 SQ (>15 CFU) CX, NoSource, Sx
13 227 ) Sheehan[49]: ,177 NA SQ (>15 CFU) CX, NoSource, ICU (2% CHG ) Sx Meffre[50]: , , 1.6 SQ (>15 CFU) (70% 0.5 CHG ) or QN (>10 3 CFU/mL) Mimoz[51]: ICU 170, , 3.9 QN (>10 3 (Biseptine ) XFU/mL) [Local or Sx] or [CX, NoSource] CX, Sx Cobett and LeBlanc[52] : 244 (70% 0.5% CHG ) 83, , 1.7 SQ (>15 CFU) NA Humar et al[53]: , , 6. SQ (>15 CFU) CX, Molec, ICU (0.5% ) NoSource * CFU colony forming units CX ICU Local: Molec NA ; NoSource: QN Sx SQ 10 Biseptine 0.25% 0.025% 4%
14 (CHG) (PI) * RR (95% CI) CHG CHG CHG RR (95% CI) CHG Maki[48] 5/214 21/ (0.10,0.66) 1/214 6/ (0.02,1.46) Sheehan[9] 3/169 12/ (0.06,0.75) 1/169 1/ (0.07,16.61) Meffre[50] 9/568 22/ (0.18,0.85) 3/568 3/ (0.20,4.77) Mimoz[51] 12/170 24/ (0.22,0.82) 3/170 4/ (0.15,2.81) Cobett and LeBlanc[52] 6/83 23/ (0.31,0.77) Humar[53] 36/116 27/ (0.87,2.04) 4/193 5/ (0.20,2.75) * CI RR CR-BSI CR-BSI Maki [48]
15 CR-BSI 16.4 [59] CR-BSI [59] CR-BSI 31 [61] CR-BSI CR-BSI [61]
16 CR-BSI [62,63]
SQ2.1 SQ2.2 ( ) 19971998 1981-97 
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
1 2
1 2 4 3 5 6 8 7 9 10 12 11 0120-889-376 r 14 13 16 15 0120-0889-24 17 18 19 0120-8740-16 20 22 21 24 23 26 25 28 27 30 29 32 31 34 33 36 35 38 37 40 39 42 41 44 43 46 45 48 47 50 49 52 51 54 53 56 55 58
3 5 6 7 7 8 9 5 7 9 4 5 6 6 7 8 8 8 9 9 3 3 3 3 8 46 4 49 57 43 65 6 7 7 948 97 974 98 99 993 996 998 999 999 4 749 7 77 44 77 55 3 36 5 5 4 48 7 a s d f g h a s d f g h a s d f g h a s d f g h j 83 83
【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
六大戦プロ編集用.PDF
+0 +2.0 +0.8 109 155 100 104 106 156 104 109 +0 0.6 109 160 103 106 103 159 102 102 161 105 111 114 105 161 10 13 12 11 157 105 150 158 111 11 112 10 164 107 10 12 13 15 11 14 165 166 16 115 113 SC 157
無印良品のスキンケア
2 3 4 5 P.22 P.10 P.18 P.14 P.24 Na 6 7 P.10 P.22 P.14 P.18 P.24 8 9 1701172 1,400 1701189 1,000 1081267 1,600 1701257 2,600 1125923 450 1081250 1,800 1125916 650 1081144 1,800 1081229 1,500 Na 1701240
1
1 2 3 4 5 0% 20% 40% 60% 80% 100% 6 7 8 0% 20% 40% 60% 80% 100% 9 0% 20% 40% 60% 80% 100% 10 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2529 (n=17) 3034 35 (n=21) (n=17) 2529 (n=19) 3034 35 (n=34) (n=64)
PowerPoint プレゼンテーション
0 1 2 3 4 5 6 1964 1978 7 0.0015+0.013 8 1 π 2 2 2 1 2 2 ( r 1 + r3 ) + π ( r2 + r3 ) 2 = +1,2100 9 10 11 1.9m 3 0.64m 3 12 13 14 15 16 17 () 0.095% 0.019% 1.29% (0.348%) 0.024% 0.0048% 0.32% (0.0864%)
untitled
186 17 100160250 1 10.1 55 2 18.5 6.9 100 38 17 3.2 17 8.4 45 3.9 53 1.6 22 7.3 100 2.3 31 3.4 47 OR OR 3 1.20.76 63.4 2.16 4 38,937101,118 17 17 17 5 1,765 1,424 854 794 108 839 628 173 389 339 57 6 18613
untitled
1. 3 14 2. 1 12 9 7.1 3. 5 10 17 8 5500 4. 6 11 5. 1 12 101977 1 21 45.31982.9.4 79.71996 / 1997 89.21983 41.01902 6. 7 5 10 2004 30 16.8 37.5 3.3 2004 10.0 7.5 37.0 2004 8. 2 7 9. 6 11 46 37 25 55 10.
2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 10mSv 15 16 17 4.46 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 3.8 2.07 2.91 1.37 2.3 1.31 1.84 1.56 1.2 1.33 2.03 0.5 1000 4000mSv 1000 4000mSv Preston et al. Radiat Res 168: 1 64,
フィナレビ106号.indb
2009 3 30 2009 4 14 CDC 2009 4 25 WHO 2009 4 26 2009 4 28 2009 4 28 2009 4 30 2009 5 1 2009 5 8 6 2009 5 9 2009 5 23 2009 6 3 2009 6 9 2500 2009 6 12 WHO 6 2009 6 28 2009 8 9 1 1 2009 8 15 2009 8 19 2010
16 23 270 5 1 2 3 1 2 3 1 2 3 6 5 54 44 9 9 4,000 118 7 5 JA 8 1 1 2 16 48,000 1 1 1 1 2 2 3 1, 312. 87 4 5 10 3 31 6 10 4 25 7 3 1 2 8 2 495. 84 1 296. 49 2 199. 35 1 124. 62 54. 50 28. 80 34. 17 54.
ACS34_07高柳.indd
1. ICU 2002 2005 2006 32 ICU 1) 2) 3) 3 2. 2.1. 123 8 (1716 1735) ICU 1736 2 1 3 4) ICU 5) 2.2. a 1923 110 30 6) 1924 15 16 7) 8) ICU 1 1935 9) 1930 1 120 10) 1936 11) 12) 124 b 1917 1927 1922 13) 14)
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
14 10 15 14 10 15 46.7 14 8 14 3 1 14 8 31 1 14 8 80,956 454,528 2.9 3.4 14,550 2.7 14,227 2.4 13 8 78,658 439,432 14,956 14,571 14 2 153,889 860,441 24,545 23,378 1 ( ) - 1-1 14 8 7,262 6.1 84 28 13 8
表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
ICU/…A…WŁ¶32/10“‡Œö
V 1. 2002 1) 2) 12 2. 60 1941 12 1944 ICU B29 87 115 105 Z 54 1944 87 44 45 177 1945 4 21 22 8 3) 3. 1941 11 1 30 1944 2 1944 1 1941 8 4) 4. 5) 6) 5 1 50 7) 1944 4 1945 3 5 8) 4 3 160 1944 5 1945 3 3 3
1 P2 P P3P4 P5P8 P9P10 P11 P12
1 P2 P14 2 3 4 5 1 P3P4 P5P8 P9P10 P11 P12 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 & 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1! 3 2 3! 4 4 3 5 6 I 7 8 P7 P7I P5 9 P5! 10 4!! 11 5 03-5220-8520
16 10 19
16 10 19 1 1 10 10 11 10 12 10 2 13 10 14 10 15 16 15 17 15 18 15 19 15 20 21 20 22 20 23 20 24 20 3 26 28 29 30 31 32 33 34 35 36 38 39 40 41 42 4 10 10 11 10 12 10 13 10 5 14 10 15 16 15 17 15 18 15
iii iv v vi 21 A B A B C C 1 1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 19 22 30 39 43 48 54 60 65 74 77 84 87 89 95 101 12 20 23 31 40 44 49 55 61 66 75 78 85 88 90 96 102 13 21 24 32 41 45 50 56 62 67 76 79
.p.t.....id
9784903922386 ISBN978-4-903922-38-6 Contents ?? R RR R R R R R R R R R R R RR R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R r r r R R r r r r Q5 A5 Q10 A10 Q11 A11 Q7 A7 Q8 A8
OVERSEAS 2011 SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS SITE OVERSEAS
1: *2 W, L 2 1 (WWL) 4 5 (WWL) W (WWL) L W (WWL) L L 1 2, 1 4, , 1 4 (cf. [4]) 2: 2 3 * , , = , 1
![1: *2 W, L 2 1 (WWL) 4 5 (WWL) W (WWL) L W (WWL) L L 1 2, 1 4, , 1 4 (cf. [4]) 2: 2 3 * , , = , 1](/thumbs/49/25412084.jpg "1: *2 W, L 2 1 (WWL) 4 5 (WWL) W (WWL) L W (WWL) L L 1 2, 1 4, , 1 4 (cf. [4]) 2: 2 3 * , , = , 1")
I, A 25 8 24 1 1.1 ( 3 ) 3 9 10 3 9 : (1,2,6), (1,3,5), (1,4,4), (2,2,5), (2,3,4), (3,3,3) 10 : (1,3,6), (1,4,5), (2,2,6), (2,3,5), (2,4,4), (3,3,4) 6 3 9 10 3 9 : 6 3 + 3 2 + 1 = 25 25 10 : 6 3 + 3 3
T T T T A 0 1 A 1 A P (A 1 ) = C 1 6 C 8C 3 = 15 8, P (A ) = C 6 C 1 8C 3 = 3 8 T 5 B P (A 1 B) = =
4 1.. 3. 4. 1. 1 3 4 5 6 1 3 4 5 6. 1 1 1 A B P (A B) = P (A) + P (B) P (C) = P (A) P (B) 3. 1 1 P (A) = 1 P (A) A A 4. A B P A (B) = n(a B) n(a) = P (A B) P (A) 50 015 016 018 1 4 5 8 8 3 T 1 3 1 T T
産衛誌57-4たより.indb
A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al
Q E Q T a k Q Q Q T Q =
i 415 q q q q Q E Q T a k Q Q Q T Q = 10 30 j 19 25 22 E 23 R 9 i i V 25 60 1 20 1 18 59R1416R30 3018 1211931 30025R 10T1T 425R 11 50 101233 162 633315 22E1011 10T q 26T10T 12 3030 12 12 24 100 1E20 62
¹₄ ³₈ ³₈ ¹₂ ¹₂ ¹₂ ³₄ ³₄
33 4 5 2 63 2 1 3 1 4 2 5 6 19 ¹₄ ³₈ ³₈ ¹₂ ¹₂ ¹₂ ³₄ ³₄ 1 1 5 6 6 7 1 1 1 1 1 1 35 GDC LB 1 1 Y 2 A54 2 1 2 1 1 5 1 1 21 1 2 2 2 53 512 53 53 512 3 12 2 2 4 5 63 1 1 2 4 5 63 1 1 2 45 1 5 2 3 4 4 3 4 4
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
平成12年度 証券貯蓄に関する全国調査
24.6 22.9 5.4 59.6 2.1 3.3 2.5 2.0 1.1 91.7 12.2 28.6 58.6 (NA:0.6) 32.9 30.7 12.3 3.3 4.5 49.5 87.6 61.5 5.1 58.7 48.9 10.5 5.9 8.6 14.9 0.8 20.8 8.8 6.8 2.5 2.2 5.5 25.6 10.4 8.9 9.4 9.0 11.8 9.3 8.7
contents
contents 1 4 8 10 12 14 1. 2. 78 79 16 17 18 20 21 21 22 23 23 24 26 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 1. 2. 3. 4. 5. 6. 7. 8. 9. 28 30 30 32 34 35 36 36 45 46 48 52 60 69 70 71 71 72 74 76 76 1. 2. 3.
報告書
1 2 3 4 5 6 7 or 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2.65 2.45 2.31 2.30 2.29 1.95 1.79 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 60 55 60 75 25 23 6064 65 60 1015
P VQ7.indd
-6-8 -8-6 -6/7-8 Series ISOSizeSize2 68 SJ SV J SZ V V4 S0700 VQ VQ4 VQ VQC VQC4 VQZ SQ VS VR -6-G-S-02-6-G-S-0 ø ø ø ø ø ø ø ø ø ø -6-G-S-R02 ø ø ø ø ø ø ø ø ø ø -6-G-S-R0 686 -8-G-S-0-8-G-S-R0-8-G-S-04-8-G-S-R04
untitled
ACCESS N POINT 5 POINT 1 POINT 6 POINT 2 NEWS POINT 3 POINT 4 NEWS 01 HANNAN UNIVERSITY 2014 02 03 HANNAN UNIVERSITY 2014 04 START CONTENTS 01 03 04 05 07 09 11 12 13 14 15 17 18 19 20 21 22 23 25 27 28
01-表紙.ai
B 0 5 0-5 双極子核 I=1/ 2 四極子核 I 1 e Li Be B C N F Ne Na Mg 黒字はNMR 観測不可 Al Si P S Cl Ar K Ca Sc Ti V Cr MnFe Co Ni Cu ZnGaGe As Se Br Kr RbSr Y Zr NbMoTc RuRhPdAgCd In Sn SbTe I Xe Cs Ba La f Ta W Res Ir Pt
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
0 (18) /12/13 (19) n Z (n Z ) 5 30 (5 30 ) (mod 5) (20) ( ) (12, 8) = 4
0 http://homepage3.nifty.com/yakuikei (18) 1 99 3 2014/12/13 (19) 1 100 3 n Z (n Z ) 5 30 (5 30 ) 37 22 (mod 5) (20) 201 300 3 (37 22 5 ) (12, 8) = 4 (21) 16! 2 (12 8 4) (22) (3 n )! 3 (23) 100! 0 1 (1)
sikepuri.dvi
2009 2 2 2. 2.. F(s) G(s) H(s) G(s) F(s) H(s) F(s),G(s) H(s) : V (s) Z(s)I(s) I(s) Y (s)v (s) Z(s): Y (s): 2: ( ( V V 2 I I 2 ) ( ) ( Z Z 2 Z 2 Z 22 ) ( ) ( Y Y 2 Y 2 Y 22 ( ) ( ) Z Z 2 Y Y 2 : : Z 2 Z
-2-
-1- -2- -3- 1 2 Pseudomonas avenae 34 36 3 25 20 4 1 200 300 2 18 20 5 24 10 ml 20 12 24 3-4- 4 32 33 3 1 60 30 3cm 1 2 1 3 1 3 2 3 1 2 1 1 3 2 2 1 300 3 1 5 0 1 1 2 2 3 3 4-5- 1nl 2n2 3n3 4n4 4N 100 N
10 12 13 16 17 26 26 31 32 33 33 35 37 38 39 42 43 44 2 15 5 15 57 17 16 4 16 4 2 JA 16 7 1 10 22 11 9 12 6 12 2 12 24 17 1 6 JA 3 4 5 16 7 1 6 ( ) ( ) 15 ( ) ( ) ( ) ( ) ( ) 16 3 35 37 1 93 223 ( ) 218
ISO
ISO ISO ISO(International Standardization Organization) 135 ISO CD(Committee Draft) DIS(Draft for International Standard) FDIS(Final DIS) ISO ISO23500 2004.01.13 ANSI/AAMI RD52 2004.04.13 6 2004.08.09
4_Laser.dvi
1 1905 A.Einstein 1917 A.Einstein 1954 C.H.Townes MASER Microwave Amplification by Stimulated Emission of Radiation 23.9 GHz 1.26 cm 1960 T.H.Maiman LASER Light Amplification by Stimulated Emissin of Radiation
橡scb79h16y08.PDF
S C B 05 06 04 10 29 05 1990 05 0.1 90 05 0.2 06 90 05 06 06 04 04 10 1.9 90 12 2.0 13 10 10 18.0 16.0 6.1 1 10 1.7 10 18.5 0.8 03 04 1 04 42.9 10 20.5 10 4.2 0.7 0.2 0.6 01 00 100 97 11 102.5 04 91.5
1 2003 5.31 [ / ] 2 2003 6.21 [ ] 3 2003 7.19 [ ] [ ] 4 2003 8.29 5 2003 11.8 6 2004 1.17 [() ] [() ] [ ] GEMS [ GEMS ] [ ] http://www.tepco.co.jp/environment/pw/contest/sakuhin-j.html
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
Title 多重構造音響連成場の振動解析制御 Author(s) 菅野, 秀 Citation Issue Date 2012-03-25 URL http://hdl.handle.net/10748/5587 DOI Rights Type Thesis or Dissertation Textversion publisher http://www.tmu.ac.jp/ 首都大学東京機関リポジトリ
2 $ 0.41 $ 0.06 $ 0.44 $ (0.05) -- (0.05) (0.32) (0.02)
NEWS RELEASE $ 3,214 $ 3,222 - $ 12,037 $ 11,968 1% $ 521 $ 461 13% $ 1,956 $ 1,867 5% $ 3,735 $ 3,683 1% $ 13,993 $ 13,835 1% $ 3,735 $ 3,407 10% $ 13,993 $ 12,933 8% $ 554 $ 86 549% $ 597 $ 1,501 (60)%
2 A. Ramón y Cajal projectional brain map barrel Statview I I II II I I II II
1 B version1.3 A. B. C. D. E. F. G. H. 2 A. Ramón y Cajal projectional brain map barrel Statview I I II II I I II II . B-1-b 3 B-1-c 4 _m _m _m µ µ 5 Rieke et al. (1997) Spikes-Exploring the Neural Code
.
2015 総合カタログ 電解コンデンサ (S-Cap/ 導電性高分子アルミ電解コンデンサ ) 2015. 1 industrial.panasonic.com/jp/ . ESR ESRESL CX 7.3 4.3 1.9 mm 2 V 560 μf ~ 6.3 V 180μF ESR : 12 mω, 15 mω GX 7.3 4.3 1.9 mm 2 V 560 μf ~ 2.5 V 470 μf
untitled
BALL BUSH UNIT SN-A SN-10A SNF-A SNF-10A Copyright 011 ASK Limited all rights reserved. EXCLUSIVE SHAFTS Copyright 011 ASK Limited all rights reserved. Copyright 011 ASK Limited all rights reserved. EXCLUSIVE
1 LCR R Q 2 2.1 1 LCR E I I = R 2 + E ( ωl 1 ωc ) 2 (1) ω ω 0 = 1 LC (2) ω 0 = 2πf 0 f 0 = 1/(2π LC) I 0 = E R (3) 1 2 R I 0 Q (sharpness of resonance
E-3 98-76 3 1 16 9 28 65.4 % 23.7 C 1013.5 hpa 16 10 4 1 LCR R Q 2 2.1 1 LCR E I I = R 2 + E ( ωl 1 ωc ) 2 (1) ω ω 0 = 1 LC (2) ω 0 = 2πf 0 f 0 = 1/(2π LC) I 0 = E R (3) 1 2 R I 0 Q (sharpness of resonance)
262014 3 1 1 6 3 2 198810 2/ 198810 2 1 3 4 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 2... 2... 4... 5... 9... 9... 10... 10... 10... 10... 13 2... 13 3... 15... 15... 15... 16 4...
,, 2. Matlab Simulink 2018 PC Matlab Scilab 2
(2018 ) ( -1) TA Email : ohki@i.kyoto-u.ac.jp, ske.ta@bode.amp.i.kyoto-u.ac.jp : 411 : 10 308 1 1 2 2 2.1............................................ 2 2.2..................................................
環境感染誌 Vol.28no.3,2013 因菌となる皮膚菌叢の 80 は表皮角層表層の上部 5 層に常在することが報告されていることから 6), カテーテル挿入部位の消毒は, 感染対策のターゲットとして重要である. CRBSI 起因菌のうち重要な菌種としては, コアグラーゼ陰性ブドウ球菌 (Coa
原著 カテーテル関連血流感染予防に向けた皮膚消毒薬としての 1w/v クロルヘキシジン (CHG) エタノールの有効性と安全性 西原豊 1, 梶浦工 1, 横田勝弘 小林伊 菅原えりさ 大久保憲 Use of 1 w/v Chlorhexidine Gluconate in Alcohol Formulation for Reducing The Risk of Catheter-Related Bloodstream
ito.dvi
1 2 1006 214 542 160 120 160 1 1916 49 1710 55 1716 1 2 1995 1 2 3 4 2 3 1950 1973 1969 1989 1 4 3 3.1 3.1.1 1989 2 3.1.2 214 542 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
第６章.indd
60 1 1 60 Mountford, 2013 2 Hassell & Perrewe, 1995; Karpinska et al., 2013; Leisink & Knies, 2011 Kooij & Van de Voorde, 2015 Armstrong- Stassen, 2008 Armstrong-Stassen & Usel, 2009 Kanfer & Ackerman,
c a a ca c c% c11 c12 % s & %
c a a ca c c% c11 c12 % s & % c13 c14 cc c15 %s & % c16 c211 c21% c212 c21% c213 c21% c214 c21% c215 c21% c216 c21% c23 & & % c24 c25 c311 c312 % c31 c315 c32 c33 c34 % c35 c36 c37 c411 c N N c413 c c414c